211310-10-0

Basic information

• Product Name: 1-BOC-2-(METHOXY-METHYL-CARBAMOYL)PIPERIDINE
• Synonyms: N-BOC-2-(METHOXY-METHYL-CARBAMOYL)PIPERIDINE;1-BOC-2-(METHOXY-METHYL-CARBAMOYL)PIPERIDINE;1-[Tert-Butyloxycarbonyl]-2-[N-methoxy-N-methylcarbamoyl]piperidine;1-Boc-2-(N-Methoxy-N-MethylcarbaMoyl)piperidine;1-Piperidinecarboxylic acid, 2-[(MethoxyMethylaMino)carbonyl]-, 1,1-diMethylethyl ester;1-N-Boc-2-(methoxymethylcarbamoyl)piperidine;tert-butyl 2-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate;1-BOC-2-(METHOXY-METHYL-CARBAMOYL)PIPERIDINE(WX665160)
• CAS NO: 211310-10-0
• Molecular Formula: C₁₃H₂₄N₂O₄
• Molecular Weight: 272.34
• Mol File: 211310-10-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-BOC-2-(METHOXY-METHYL-CARBAMOYL)PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-2-(METHOXY-METHYL-CARBAMOYL)PIPERIDINE(211310-10-0)
• EPA Substance Registry System: 1-BOC-2-(METHOXY-METHYL-CARBAMOYL)PIPERIDINE(211310-10-0)

Safety Data

• Hazardous Substances Data: 211310-10-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Organic Synthesis:
1-BOC-2-(METHOXY-METHYL-CARBAMOYL)PIPERIDINE is used as a reagent in organic synthesis and pharmaceutical research for its ability to act as a useful intermediate in the synthesis of various pharmaceutical drugs, agrochemicals, and other fine chemicals.
Used as a Protecting Group in Organic Chemistry:
In the field of organic chemistry, 1-BOC-2-(METHOXY-METHYL-CARBAMOYL)PIPERIDINE is used as a protecting group for amines and other reactive functional groups, which is crucial for the synthesis of complex organic molecules.
Used in the Preparation of Peptide and Peptide-Based Compounds:
1-BOC-2-(METHOXY-METHYL-CARBAMOYL)PIPERIDINE also finds applications in the preparation of peptide and peptide-based compounds, which are essential in the development of new drugs and therapeutic agents.
Overall, 1-BOC-2-(methoxy-methyl-carbamoyl)piperidine is an important chemical intermediate with diverse applications in the field of drug discovery and organic chemistry.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 4043-87-2 pipecolic Acid 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 98303-20-9 1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid 
• 1117-97-1 N,0-dimethylhydroxylamine 

Downstream Products

• 1422193-31-4 2-[2-(2-aminophenyl)-1-methylvinyl]piperidine-1-carboxylic acid tert-butyl ester 
• 1422193-39-2 (Z)-1-Boc-2-(1-(2-azidophenyl)prop-1-en-2-yl)piperidine 
• 1422192-38-8 (Z)-2-(1-(2-azidophenyl)prop-1-en-2-yl)-1-(phenylsulfonyl)piperidine 
• 2407-99-0 hexahydroindolizin-7(1H)-one 
• 201991-24-4 1-tert-butoxycarbonyl-2-acetylpiperidine 
• 138371-52-5 1,1-dimethylethyl 2-benzoyl-1-piperidinecarboxylate 
• 157634-02-1 tert-butyl 2-formylpiperidine-1-carboxylate 

Relevant articles and documents

Construction of azaspirocyclic skeletons mediated by the carbonyl of the Weinreb amide: Formal total synthesis of (±)-cephalotaxine

A facile Stevens rearrangement of the Weinreb amide and the subsequent key steps mediated by the carbonyl of the Weinreb amide led to the construction of azaspirocyclic skeletons of some typical alkaloids. And the formal total synthesis of (±)-cephalotaxine was completed via a shorter synthetic route by this efficient method. Further studies on the development and asymmetric synthesis application of this strategy are underway. This journal is

Formal Fluorinative Ring Opening of 2-Benzoylpyrrolidines Utilizing [1,2]-Phospha-Brook Rearrangement for Synthesis of 2-Aryl-3-fluoropiperidines

A ring expansion of 2-benzoylpyrrolidines, which involves the formal fluorinative ring opening utilizing the [1,2]-phospha-Brook rearrangement under Br?nsted base catalysis and a subsequent intramolecular reductive amination, was developed. The operationally simple three-step protocol provides an efficient access to 2-aryl-3-fluoropiperidines. The methodology was further applied to the syntheses of azepanes and tetrahydroquinolines.

MODIFIED PROTEINS AND PROTEIN DEGRADERS

Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.

Synthetic Cathinone Analogues Structurally Related to the Central Stimulant Methylphenidate as Dopamine Reuptake Inhibitors

Synthetic cathinones are, primarily, stimulant drugs of abuse that act at monoamine transporters (e.g., the dopamine transporter or DAT) as releasing agents or as reuptake inhibitors. In the past few years, the emergence of >150 new synthetic cathinones has attracted considerable attention from medical and law enforcement communities. threo-Methylphenidate (tMP), used clinically for the treatment of ADHD and narcolepsy, is also a DAT reuptake inhibitor. tMP is somewhat structurally similar to abused cathinone stimulants, and the structure-activity relationships (SAR) of tMP have been well-defined. Hence, available tMP literature might assist in understanding the SAR of synthetic cathinones, about which less is known. In the present study, we synthesized and examined eight 2-benzoylpiperidine analogues (4, 6-12) to determine if tMP SAR might be applicable to cathinone SAR. The benzoylpiperidine analogues were evaluated in a competition assay using live-cell imaging against APP+ in HEK293 cells stably expressing hDAT and in cells coexpressing DAT and voltage-gated Ca2+ channels. All compounds were found to be DAT reuptake inhibitors, and a significant correlation was obtained between the potency of the benzoylpiperidines and tMP binding data (r = 0.91), suggesting that the SAR of tMP analogues might be directly applicable to certain synthetic cathinones as DAT reuptake inhibitors.

Rh2(II)-catalyzed selective aminomethylene migration from styryl azides

Rh2(II)-Carboxylate complexes were discovered to promote the selective migration of aminomethylenes in β,β-disubstituted styryl azides to form 2,3-disubstituted indoles. Mechanistic data are also presented that suggest that the migration occurs stepwise before diffusion of the iminium ion.

Hit-to-lead optimization of disubstituted oxadiazoles and tetrazoles as mGluR5 NAMs

Here we report the discovery and early SAR of a series of mGluR5 negative allosteric modulators (NAMs). Starting from a moderately active HTS hit we synthesized 3,5-disubstituted-oxadiazoles and tetrazoles as mGluR5 NAMs. Based on the analysis of ligand e

Microwave-assisted synthesis of novel (5-nitropyridin-2-yl)alkyl and (5-nitropyridin-3-yl)alkyl carbamates

A straightforward approach to novel (5-nitropyridin-2-yl)alkyl and (5-nitropyridin-3-yl)alkyl carbamate building blocks is presented in this study. Their construction is achieved by condensation of N-carbamate a- and β-amino carbonyl derivatives with l-methyl-3,5-dinitro-2-pyridone 1 under microwave irradiation. Judiciously chosen modifications in the nature of the parent carbonyl starting material has influenced the regiochemical outcome of the reaction and allowed an efficient access to novel nitrogen-containing scaffolds. Compounds sharing morphological similarities have been gathered in three libraries differing from each other in a single structural parameter.

TETRAZOLE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention relates to new compounds of formula (I) wherein Y1 and Y2 selected from the group consisting of hydrogen, halogen atom, C1-4 alkyl, C1-4 alkoxy or cyano group, X is oxygen or two hydrogen a

BICYCLIC UNSATURATED TERTIARY AMINE COMPOUND

The present invention provides a bicyclic unsaturated tertiary amine compound capable of inhibiting the production of inflammatory cytokines.A compound of the following formula (1): (wherein, A represents pyrrole or pyrazole, R1 represents an aryl group or a heteroaryl group which may be substituted, R2 represents a heteroaryl group which may be substituted, and R3 represents an indolizine group), or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or other pharmacologically acceptable derivative thereof.

TRICYCLIC COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE

A compound of the formula: wherein R1 is a 5- or 6-membered ring; ???Z1 is a 5- or 6-membered aromatic ring; ???Z2 is a group of -Z2a-W2-Z2b-, wherein Z2a and Z2b are each O, S(O)q (wherein q is 0, 1 or 2), an imino group, or a bond; and W2 is an alkylene chain; ???W is a group represented by wherein R3 and R3' are each a hydrogen atom, a lower alkyl group, or a lower alkoxy group; X is CH or N; n and n' are each an integer of 0 or 1 to 4; m and m' are each 1 or 2; Y is O, S(O)p (wherein p is 0, 1 or 2), CH2 or NR4 (wherein R4 is a hydrogen atom, a lower alkyl group, or a lower acyl group); and ???R2 is (1) an amino group, in which the nitrogen atom may be converted to a quaternary ammonium or an oxide, or (2) a nitrogen-containing heterocyclic group which may contain a sulfur atom or an oxygen atom as the ring-constituting atom, in which the nitrogen atommay be converted to a quaternary ammonium or an oxide; or a salt thereof. The compound exhibits excellent CCR antagonist activity against CCR5, and is useful as a prophylactic and/or therapeutic agent for HIV infection in human peripheral blood mononuclear cells, especially for AIDS.